Business Context and Reporting Period
This Form 6-K filing by Galmed Pharmaceuticals Ltd. covers the month of June 2026. The report details the consummation of the acquisition of Colospan Ltd. on June 22, 2026, following an initial announcement on June 8, 2026. The filing primarily addresses amendments to the Share Purchase Agreement (SPA) regarding the consideration structure.
Key Financial Metrics and Transaction Terms
The filing does not provide standard operating financial metrics such as revenue, profit, cash flow, or margins for Galmed Pharmaceuticals Ltd. for the reporting period. Instead, it outlines the financial terms of the Colospan acquisition:
- Total Cash Consideration: $3,300,000 payable at closing.
- Consideration Structure Change: The original plan to issue $2.0 million in Galmed ordinary shares was replaced with an additional $800,000 in cash.
- Earnout Consideration: Up to $2.0 million in performance-based payments tied to cumulative "Net Sales Revenues."
- Earnout Terms:
- Accrual begins July 1, 2027.
- No payment on the first $5 million of cumulative sales.
- 7% on sales between $5 million and $12 million.
- 9% on sales above $12 million.
- Capped at $2.0 million total.
- Acceleration Triggers: Unpaid earnout accelerates upon a qualifying sale/licensing of Colospan or if Galmed completes equity financings totaling at least $17.5 million post-closing.
Material Changes Versus Prior Period
The primary material change is the amendment to the acquisition agreement announced on June 8, 2026. The consideration mix shifted from a combination of cash and equity to a higher cash component ($3.3 million total cash vs. the previous structure involving $2.0 million in equity). The filing states that all other information from the June 8, 2026 report remains unchanged except as superseded by these amendments.
Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The acquisition was consummated on June 22, 2026. Unaudited pro forma financial statements for the year ended December 31, 2025, reflecting the revised consideration structure, are attached as Exhibit 99.1.
Risks and Contingencies: The filing cautions shareholders that investing in Galmed carries risks, specifically referencing the "Risk Factors" in the original June 8, 2026 filing. Investors are urged to review the business description and risk factors related to Colospan before making investment decisions.
Unusual Items: The filing notes that the earnout payments are subject to acceleration if Galmed raises significant equity capital ($17.5 million) or sells the acquired assets.
Key Facts for Investor Verification
- Verify the full text of the Amended Share Purchase Agreement (Exhibit 10.1) for detailed definitions of "Net Sales Revenues" and exclusions.
- Review the Unaudited Pro Forma Financial Statements (Exhibit 99.1) to understand the impact of the acquisition on Galmed's balance sheet and liquidity.
- Confirm the specific risk factors associated with Colospan's business as referenced in the original June 8, 2026 filing.
- Monitor Galmed's future equity financing activities, as raising $17.5 million would trigger immediate payment of the remaining earnout.